Table 9 Comparison between patients with and without fibrosis regression regarding different laboratory parameters, liver stiffness, and other fibrosis scoring systems

From: Angiopoietin-2 as a predictor of fibrosis regression in chronic hepatitis C virus patients after direct-acting antiviral drugs

		Group				T-Test
		Regression		Non-regression		t	P-value
T-test						t	P-value
PLT	Range	84–426		92–325		2.789	0.008*
	Mean ±SD	276.367±86.146		190.400±78.543
AST	Range	22–64		25–70		−3.648	0.001*
	Mean ±SD	33.200±10.350		49.400±16.715
ALT	Range	25–65		28–63		−2.771	0.009*
	Mean ±SD	35.867±8.908		45.700±11.963
Bilirubin	Range	0.3–1.4		0.53–2		−5.588	<0.001*
	Mean ±SD	0.676±0.243		1.356±0.528
INR	Range	0.89–1.4		1.05–1.6		−5.303	<0.001*
	Mean ±SD	1.059±0.087		1.320±0.228
Albumin	Range	3.4–4.6		3–4.1		3.148	0.003*
	Mean ±SD	3.967±0.315		3.600±0.330
Chi-square		N	%	N	%	χ²	P-value
Fibrosis staging	F0–F3	29	96.67	4	40.00	16.681	<0.001*
	F4	1	3.33	6	60.00
T-test						t	P-value
LSM	Range	2.5–14.7		7.9–16.3		−4.255	<0.001*
	Mean ±SD	7.863±2.829		12.240±2.776
FIB-4	Range	0.47–4.72		0.8–5.16		−3.958	<0.001*
	Mean ±SD	1.172±0.751		2.541±1.404
APRI	Range	0.2–1.9		0.2–1.6		−3.460	0.001*
	Mean ±SD	0.360±0.311		0.810±0.472

*significant

Back to article page